SCHEMBL12900596

SCHEMBL12900596

CCOC(=O)Cc1ccc(C)c(-c2ccc(C)cc2C=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.42
NLRP3 Q96P20 1/20 0.40
CYP4Z1 Q86W10 1/20 0.40
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.36
F2 P00734 1/20 0.36
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136891 0.87 ABL1 (0.46) SRCALDH1A1L3MBTL1ABL1RIN1
SCHEMBL137851 0.81 PTGER1 (0.43) ALDH1A1
SCHEMBL30349571 0.81 CYP4Z1 (0.47) NLRP3CYP4Z1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL26090095 0.81 CYP4Z1 (0.47) NLRP3CYP4Z1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL12900613 0.80 NLRP3 (0.41) NLRP3CYP4Z1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL137412 0.77 ABL1 (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPTABL1
SCHEMBL16501927 0.77 SRC (0.39) SRCCYP4Z1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL137666 0.77 SRC (0.39) SRCNLRP3CYP4Z1ALDH1A1L3MBTL1
SCHEMBL137399 0.77 SRC (0.41) SRCALDH1A1SMN1; SMN2L3MBTL1NPC1
SCHEMBL134607 0.77 ABL1 (0.47) SRCALDH1A1SMN1; SMN2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9572785-B2 DP2 antagonist and uses thereof BRICKELL BIOTECH, INC. (US) 2017-02-21 US disclosed
US-20160136119-A1 DP2 ANTAGONIST AND USES THEREOF BRICKELL BIOTECH, INC. 2016-05-19 US disclosed
US-8815917-B2 DP2 antagonist and uses thereof PANMIRA PHARMACEUTICALS, LLC (US) 2014-08-26 US disclosed
US-20110034558-A1 DP2 Antagonist and Uses Thereof AMIRA PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034558-A1 DP2 Antagonist and Uses Thereof PTGER2, PTGES2, PTGDR2 SRC 4449/4885NLRP3 1845/4885CYP4Z1 2956/4885
US-20160136119-A1 DP2 ANTAGONIST AND USES THEREOF PTGER2, PTGES2, PTGDR2 SRC 4449/4885NLRP3 1845/4885CYP4Z1 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.